CeriBell (NASDAQ:CBLL) Director Joseph Michael Taylor Sells 13,095 Shares

CeriBell, Inc. (NASDAQ:CBLL) Director Joseph Michael Taylor sold 13,095 shares of CeriBell stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $23.40, for a total transaction of $306,423.00. Following the transaction, the director directly owned 48,478 shares in the company, valued at approximately $1,134,385.20. This represents a 21.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Joseph Michael Taylor also recently made the following trade(s):

• On Thursday, June 11th, Joseph Michael Taylor sold 5,500 shares of CeriBell stock. The shares were sold at an average price of $18.41, for a total transaction of $101,255.00.

CeriBell Stock Performance

Shares of CeriBell stock opened at $23.33 on Friday. The stock’s fifty day simple moving average is $18.93 and its 200 day simple moving average is $19.11. The company has a current ratio of 9.18, a quick ratio of 10.01 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $895.41 million, a PE ratio of -13.26 and a beta of 0.81. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $24.33.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The business had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. On average, research analysts predict that CeriBell, Inc. will post -1.96 EPS for the current year.

Institutional Trading of CeriBell

Several institutional investors and hedge funds have recently bought and sold shares of CBLL. BlackRock Inc. bought a new position in CeriBell in the second quarter valued at approximately $37,657,000. Vanguard Group Inc. increased its position in shares of CeriBell by 11.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after purchasing an additional 147,013 shares during the last quarter. KCM Capital Inc raised its stake in shares of CeriBell by 40.0% during the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock worth $25,662,000 after purchasing an additional 400,000 shares in the last quarter. Yu Fan boosted its holdings in shares of CeriBell by 10.7% in the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after buying an additional 130,964 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of CeriBell by 1,945.9% in the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after buying an additional 1,162,200 shares during the last quarter.

Analyst Ratings Changes

A number of analysts recently issued reports on CBLL shares. BTIG Research reissued a “buy” rating and set a $28.00 target price on shares of CeriBell in a research note on Tuesday. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Finally, Canaccord Genuity Group upped their price target on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, CeriBell currently has an average rating of “Moderate Buy” and an average target price of $22.00.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.